# Global Health (NSE: MEDANTA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MEDANTA · Pivot · prices to 22 Oct 2026

Global Health (NSE: MEDANTA) closed at ₹1,215.10 on 22 Oct 2026, down 1.65% on the day. With a market capitalisation of ₹32,216 Cr, it ranks 256th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 58.9× trailing earnings, against a return on equity of 14.0% in FY26. Over the past year the share price has fallen 10.1%. Its 52-week range is ₹956.00 (30 Mar 2026) to ₹1,544.00 (27 Aug 2026); the last close is 21.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,304 Cr (+26.5% year on year) and net profit ₹157 Cr (−1.1%), on a consolidated basis. Promoters held 33.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,215.10 |
| Market cap | ₹32,216 Cr |
| P/E (trailing) | 58.9 |
| ROE | 14.0% (FY26) |
| ROCE | 15.1% (FY26) |
| Debt to equity | 0.3 |
| 52-week high | ₹1,544.00 (27 Aug 2026) |
| 52-week low | ₹956.00 (30 Mar 2026) |
| 1-year return | −10.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹1,304 Cr | +26.5% | ₹157 Cr | −1.1% | ₹5.91 |
| Q4 FY26 | ₹1,159 Cr | +24.5% | ₹142 Cr | +39.7% | ₹5.36 |
| Q3 FY26 | ₹1,121 Cr | +18.8% | ₹95 Cr | −33.5% | ₹3.54 |
| Q2 FY26 | ₹1,099 Cr | +14.9% | ₹158 Cr | +21.1% | ₹5.89 |
| Q1 FY26 | ₹1,031 Cr | +19.7% | ₹159 Cr | +49.6% | ₹5.92 |
| Q4 FY25 | ₹931 Cr | +15.2% | ₹101 Cr | −20.4% | ₹3.77 |
| Q3 FY25 | ₹943 Cr | +13.3% | ₹143 Cr | +15.6% | ₹5.32 |
| Q2 FY25 | ₹957 Cr | +13.3% | ₹131 Cr | +4.5% | ₹4.87 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹3,692 Cr | ₹481 Cr |
| FY24 | ₹3,275 Cr | ₹478 Cr |
| FY23 | ₹2,694 Cr | ₹326 Cr |
| FY22 | ₹2,167 Cr | ₹196 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 33.00%
- Foreign institutions: 9.46%
- Domestic institutions: 16.89%
- Non-institutions: 40.56%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,691.90 | ₹34,602 Cr | 42.4 | 17.8% |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,812 Cr | 145.1 | 18.7% |
| [Dr. Lal Path Labs](https://app.pivotnow.in/stock/LALPATHLAB) | ₹1,838.50 | ₹30,907 Cr | 58 | 20.1% |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,889.60 | ₹30,150 Cr | 144.8 | 4.3% |
| [Sai Life Sciences](https://app.pivotnow.in/stock/SAILIFE) | ₹1,396.80 | ₹29,633 Cr | 85.1 | 8.0% |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹671.30 | ₹28,080 Cr | 111.9 | 18.0% |

## Questions and answers

### What is the share price of Global Health today?

Global Health (NSE: MEDANTA) last closed at ₹1,215.10 on 22 Oct 2026. Its 52-week high is ₹1,544.00 and its 52-week low is ₹956.00.

### What is the market cap of Global Health?

Global Health's market capitalisation is ₹32,216 Cr (₹32,216 Cr) at the 22 Oct 2026 close, ranking 256th among the NSE companies Pivot tracks.

### What is the P/E ratio of Global Health?

Global Health trades at a trailing P/E of 58.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.

### What is the ROE and ROCE of Global Health?

Return on equity was 14.0% in FY26 and return on capital employed was 15.1% in FY26 (consolidated figures).

### Is Global Health a debt-free company?

No. Global Health's debt-to-equity ratio was 0.3 in FY26, with total debt of ₹1,127 Cr.

### What were Global Health's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Global Health reported revenue of ₹1,304 Cr, +26.5% year on year, and net profit of ₹157 Cr, −1.1% year on year.

### How has Global Health stock performed over the last year?

Global Health's share price has fallen 10.1% over the past year, −10.3% over three months and −19.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Global Health?

As of 30 Jun 2026: promoters 33.00%, foreign institutions 9.46%, domestic institutions 16.89%, non-institutions 40.56%.

### Who are Global Health's competitors?

The listed Pharma & Healthcare companies closest to Global Health by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Dr. Lal Path Labs, Wockhardt, Sai Life Sciences and Krishna Institute of Medical Sciences.

### Is Global Health a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Global Health's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MEDANTA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.